Glessner Coleen (CIK 1919170) reported 13 SEC Form 4 insider transactions across 1 companies over the past 18 months (most recent 2026-06-10). Recent activity: Sell EBS (2,018 shares), Buy EBS (100,111 shares), Sell EBS (8,199 shares), Sell EBS (313 shares), Sell EBS (28,847 shares). Source: SEC Form 4.
| Date | Company | Role | Type | Shares | Value |
|---|---|---|---|---|---|
| 2026-06-10 | Emergent BioSolutions Inc. (EBS) | EVP, Quality & Ethics, and CPL | Sell | 2,018 | $16,144 |
| 2026-05-01 | Emergent BioSolutions Inc. (EBS) | EVP, Quality & Ethics, and CPL | Buy | 100,111 | $0 |
| 2026-03-05 | Emergent BioSolutions Inc. (EBS) | EVP, Quality & Ethics, and CPL | Sell | 8,199 | $69,200 |
| 2026-03-03 | Emergent BioSolutions Inc. (EBS) | EVP, Quality & Ethics, and CPL | Sell | 313 | $2,551 |
| 2026-02-10 | Emergent BioSolutions Inc. (EBS) | EVP, Quality & Ethics, and CPL | Sell | 28,847 | $315,009 |
| 2026-02-10 | Emergent BioSolutions Inc. (EBS) | EVP, Quality & Ethics, and CPL | Sell | 2,852 | $31,144 |
| 2025-10-16 | Emergent BioSolutions Inc. (EBS) | EVP, Quality & Ethics, and CPL | Sell | 30,608 | $306,080 |
| 2025-06-10 | Emergent BioSolutions Inc. (EBS) | EVP, Quality & Ethics, and CPL | Sell | 1,249 | $8,281 |
| 2025-04-09 | Emergent BioSolutions Inc. (EBS) | EVP, Quality & Ethics, and CPL | Sell | 480 | $2,131 |
| 2025-03-10 | Emergent BioSolutions Inc. (EBS) | EVP, Quality & Ethics, and CPL | Buy | 62,500 | $0 |
| 2025-03-04 | Emergent BioSolutions Inc. (EBS) | EVP, Quality & Ethics, and CPL | Sell | 5,913 | $0 |
| 2025-03-04 | Emergent BioSolutions Inc. (EBS) | EVP, Quality & Ethics, and CPL | Sell | 24,078 | $0 |
| 2025-03-04 | Emergent BioSolutions Inc. (EBS) | EVP, Quality & Ethics, and CPL | Sell | 313 | $2,341 |
Source: SEC Form 4 filings · as of 2026-06-10